重大事件外國發行人報告 6-K 2026-07-21

Innate Pharma 公布 ADC 新藥 IPH4502 一期臨床完成入組，年底公佈初步數據

AI 繁中摘要

Innate Pharma（巴黎泛歐交易所：IPH；納斯達克：IPHA）今日提交 6-K 表格，公佈其自主研發的 Nectin-4 抗體偶聯藥物（ADC）IPH4502 的 1 期臨床試驗（NCT06781983）劑量遞增階段已完成患者入組，目前合共 76 名患者已納入研究，涵蓋法國及美國多個中心。💰

📊 **初步數據預計今年年底公佈**，屆時將涵蓋全部 76 名患者的數據，用以指導後續劑量優化及腫瘤類型選擇。

🛡️ **安全性方面**：目前觀察到良好的安全性輪廓，尤其血液毒性有限，反映公司專有連接子能緩慢釋放游離 exatecan，從而降低副作用。此舉有望克服 MMAE 類 ADC 常見的耐藥問題（如 MDR1 介導的耐藥性），且無需進行 CYP2D6 基因分型。

🎯 **療效信號**：在既往接受過大量治療（包括已使用過 enfortumab vedotin 的尿路上皮癌患者）的晚期實體瘤中，已觀察到客觀緩解，包括非小細胞肺癌（NSCLC）及頭頸部鱗狀細胞癌（HNSCC）。這支持 IPH4502 在高未滿足醫療需求人群中的潛力。

📌 **管理層觀點**：Innate Pharma 首席醫學官 Sonia Quaratino 表示，完成劑量遞增入組是重要里程碑，目前數據支持 IPH4502 的差異化設計，尤其有限的血液毒性可能反映連接子優勢。期待年底數據出爐，以指導劑量優化並進一步明確臨床潛力。

💡 **對投資者的影響**：IPH4502 是 Innate Pharma 的核心管線資產之一，其差異化設計（專有連接子 + exatecan 載荷 + 非重疊表位抗體）有潛力在 EV 耐藥模型及低 Nectin-4 表達的腫瘤中展現活性。1 期數據將是後續開發及商業價值的關鍵催化劑，值得投資者密切關注年底的數據讀出。

展開英文正文

EX-99.1
2
a260721exhibit991.htm
EX-99.1

Document

EXHIBIT 99.1

INNATE PHARMA ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 1 DOSE ESCALATION STUDY OF IPH4502, A NOVEL NECTIN-4 EXATECAN ANTIBODY-DRUG CONJUGATE (ADC) 

Marseille, France, July 21, 2026, 7:00 AM CEST

•Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
•Favorable safety profile observed to date, with limited hematological toxicity 
•Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need

Marseille, France, July 21, 2026, 7:00 AM CEST

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and will include data from 76 patients, guiding Phase 1 dose optimization in selected tumor types.
The IPH4502-101 Phase 1 study is an open-label, multi-center study evaluating the safety, tolerability, and preliminary anti-tumor activity of IPH4502 as a single agent in patients with advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast, ovarian, gastric, esophageal, and colorectal cancers. The Phase 1 dose-escalation part has recruited 76 patients in France and the United States.
To date, IPH4502 continues to show a favorable safety profile, with limited hematological toxicity, supporting the hypothesis that the Company’s proprietary linker leads to a slow release of free exatecan, minimizing toxicity. Preliminary anti-tumor activity continues to be observed in heavily pre-treated patients with advanced solid tumors, with objective responses reported in UC post enfortumab vedotin, as well as in NSCLC and HNSCC. 
“Completing enrollment in the dose escalation marks an important milestone for IPH4502. The data generated to date continue to support the differentiated design of IPH4502, notably through the limited hematological toxicity observed to date, which we believe might reflect the benefits of our proprietary linker. We look forward to the dose escalation dataset by year-end, which will guide our path into dose optimization and further define the clinical potential of IPH4502,” said Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma.

About IPH4502
IPH4502 is Innate Pharma's proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance, and without the need for CYP2D6 genotyping. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). In preclinical studies, IPH4502 demonstrated anti-tumor activity in EV-resistant tumor models and in tumors with low and heterogeneous 

Nectin-4 expression, supporting its potential applicability across solid tumor types beyond urothelial carcinoma (UC). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4.

About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next generation antibody therapeutics. 
Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC).
Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. 
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. 
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN codeTicker codeLEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors
For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. 
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For more information
Investors & Media Relations

Innate Pharma 
Stéphanie Cornen 
[email protected] 

Investor Relations 
[email protected] 

Media 
[email protected]